Is Bafna Pharmaceuticals a Good Buy After Its Q1 FY27 Results?

Bafna Pharmaceuticals share price around Rs 302. 5.3% below 52-week high of Rs 318. Q1 FY27 revenue Rs 27 crore, down 23.2% YoY. PAT Rs 0.08 crore, down 97.6%. PE 94x.

The Bafna Pharmaceuticals share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Bafna Pharmaceuticals is a Chennai-based manufacturer of pharmaceutical formulations, with its stock on a sharp recent rally, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.

Revenue for the quarter came in at Rs 27 crore, down 23.2% year on year, while profit after tax came in at Rs 0.08 crore, down 97.6% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Bafna Pharmaceuticals share price from here.

This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Bafna Pharmaceuticals share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.

Click Here – Get Free Investment Predictions

Bafna Pharmaceuticals Q1 FY27 Financial Highlights

Bafna Pharmaceuticals Q1 FY27 Performance Analysis

Check Bafna Pharmaceuticals Fundamentals on Univest Screener

Revenue declined 23.2% for the quarter, which was not offset by cost control, and the pharmaceutical formulations manufacturing business will need a stronger showing next quarter to reverse the trend.

Profitability is where the quarter disappointed. PAT fell 98% year on year to Rs 0.08 crore with revenue also down 23.2%, which points to margin or cost pressure that management will need to address. This gap between top-line and bottom-line performance is the key thing weighing on the Bafna Pharmaceuticals share price this quarter.

Sequential quarterly data was not fully available for this comparison, so investors should track the next quarter’s results to build out the trend behind the Bafna Pharmaceuticals share price.

Key Business Factors in Q1 FY27

Revenue Trend

Bafna Pharmaceuticals’ revenue declined 23.2% year on year this quarter, taking the quarterly base to Rs 27 crore in a pharmaceutical formulations manufacturing business that remains sensitive to demand and pricing cycles that ultimately feed through to the Bafna Pharmaceuticals share price.

Profitability Trend

Profit before tax came in at Rs 0.08 crore for the quarter, against Rs 3.39 crore a year earlier, a figure worth tracking alongside the headline PAT number for a fuller picture of the quarter.

Balance Sheet Position

Bafna Pharmaceuticals’ balance sheet metrics were not fully available for this quarter and should be checked against the company’s official filings before making an investment decision.

Valuation Context

Bafna Pharmaceuticals does not carry a meaningful PE multiple this quarter given its current earnings, so investors should lean on revenue and book value trends instead of the price-to-earnings ratio when assessing the Bafna Pharmaceuticals share price.

Dividend Details

No interim dividend was declared alongside Bafna Pharmaceuticals’ Q1 FY27 results. The stock has not paid a meaningful dividend in the trailing twelve months. Investors tracking the Bafna Pharmaceuticals share price for income should watch the company’s announcements around its next annual results for any dividend decision.

Bafna Pharmaceuticals Share Price Outlook for FY27

The key question for the rest of FY27 is whether Bafna Pharmaceuticals can arrest the margin pressure seen this quarter. Revenue growth alone will not be enough to support the Bafna Pharmaceuticals share price if profitability keeps slipping, so investors should watch the next couple of quarters for signs of a turnaround in the bottom line.

A stabilising or improving margin trend in the next result would be the clearest signal that this quarter’s profit decline was a temporary setback rather than the start of a longer slide for the Bafna Pharmaceuticals share price.

Bafna Pharmaceuticals Stock Performance

Download the Univest iOS App or Univest Android App to track Bafna Pharmaceuticals’ live share price and get daily stock updates.

The Bafna Pharmaceuticals share price was trading around Rs 302 as results season played out in late August 2026, roughly 5.3% below its 52-week high of Rs 318 and well above its 52-week low of Rs 95.

The Bafna Pharmaceuticals share price has likely already absorbed some of this quarter’s disappointment, but further downside is possible if the next results confirm the same trend rather than a one-off.

Key Risks

Profitability Risk

The quarter’s profit trend is the clearest risk here. Until Bafna Pharmaceuticals shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results.

Sector and Demand Risk

As a pharmaceutical formulations manufacturing business, Bafna Pharmaceuticals’ results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Bafna Pharmaceuticals share price well before the next result.

Execution Risk

Sustaining this quarter’s trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

Conclusion

Bafna Pharmaceuticals’ Q1 FY27 results were weak on both counts, with PAT down 98% to Rs 0.08 crore, with revenue also falling 23.2%. The Bafna Pharmaceuticals share price reflects a stock in wait-and-watch mode, and it is not an obvious buy purely on this quarter’s numbers until both the topline and margin trend turn around.

Frequently Asked Questions on Bafna Pharmaceuticals Q1 FY27 Results

What were Bafna Pharmaceuticals’ Q1 FY27 results?

Ans. Bafna Pharmaceuticals reported Q1 FY27 revenue of Rs 27 crore, down 23.2% year on year, and PAT of Rs 0.08 crore, down 97.6% year on year.

Is Bafna Pharmaceuticals a good buy after its Q1 FY27 results?

Ans. Bafna Pharmaceuticals’ profitability came under pressure this quarter, which makes this a stock to watch rather than an obvious buy purely on this result. Investors should form their own view based on their own risk appetite and time horizon.

What is the Bafna Pharmaceuticals share price today?

Ans. The Bafna Pharmaceuticals share price was trading around Rs 302 in late August 2026, about 5.3% below its 52-week high of Rs 318 and well above its 52-week low of Rs 95.

What is Bafna Pharmaceuticals’ revenue and profit for Q1 FY27?

Ans. Bafna Pharmaceuticals reported revenue of Rs 27 crore and a net profit of Rs 0.08 crore for the quarter ended June 30, 2026.

Did Bafna Pharmaceuticals declare a dividend with its Q1 FY27 results?

Ans. No interim dividend was declared alongside Bafna Pharmaceuticals’ Q1 FY27 results. Investors should track the company’s next annual results for any dividend announcement.

What is Bafna Pharmaceuticals’ PE ratio and is it expensive?

Ans. The Bafna Pharmaceuticals share price trades at a trailing PE of 93.8x. Investors should compare this with the company’s growth rate before judging value.

What are the key risks for Bafna Pharmaceuticals investors right now?

Ans. The quarter’s profit trend is the clearest risk here. Until Bafna Pharmaceuticals shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results. Sustaining this quarter’s trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

What is Bafna Pharmaceuticals’ promoter shareholding?

Ans. Promoter shareholding data for Bafna Pharmaceuticals was not fully available for this quarter and should be checked on the company’s official filings.